Small interfering RNA to treat pancreatic cancer

DC Julien, A Giri, RA Hill

Research output: Other contribution to conferenceAbstractpeer-review

Abstract

Most pancreatic cancers possess point mutations in the K-Ras oncogene. The majority of K-Ras point mutations result in K-Ras being constitutively activated leading to increased cell proliferation, growth, and inhibition of apoptotic pathways. Studies have suggested that small interfering RNA (siRNA) designed against mutated K-Ras (mK-Ras) may be a treatment option for pancreatic cancers. The aim of this study was to characterize the effects of mK-Ras siRNA on cell viability, proliferation, and metabolic activity in pancreatic cancer cell lines.
Original languageEnglish
Pages140
Number of pages1
DOIs
Publication statusPublished - 2013
EventWestern Regional Meeting of the American Federation for Medical Research - Carmel, United States
Duration: 24 Jan 201326 Jan 2013
http://afmr.org/archives/2013/Western-Regional.cgi

Conference

ConferenceWestern Regional Meeting of the American Federation for Medical Research
Country/TerritoryUnited States
CityCarmel
Period24/01/1326/01/13
Internet address

Fingerprint

Dive into the research topics of 'Small interfering RNA to treat pancreatic cancer'. Together they form a unique fingerprint.

Cite this